T. Rowe Price Associates’s Revolution Medicines RVMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $173M | Sell |
4,701,962
-897,680
| -16% | -$33M | 0.02% | 465 |
|
|
2025
Q1 | $198M | Sell |
5,599,642
-266,320
| -5% | -$9.42M | 0.02% | 420 |
|
|
2024
Q4 | $257M | Buy |
5,865,962
+552,657
| +10% | +$24.2M | 0.03% | 376 |
|
|
2024
Q3 | $241M | Buy |
5,313,305
+96,646
| +2% | +$4.38M | 0.03% | 397 |
|
|
2024
Q2 | $202M | Buy |
5,216,659
+402,349
| +8% | +$15.6M | 0.02% | 415 |
|
|
2024
Q1 | $155M | Buy |
4,814,310
+177,957
| +4% | +$5.74M | 0.02% | 468 |
|
|
2023
Q4 | $133M | Sell |
4,636,353
-458,353
| -9% | -$13.1M | 0.02% | 493 |
|
|
2023
Q3 | $141M | Buy |
5,094,706
+75,941
| +2% | +$2.1M | 0.02% | 448 |
|
|
2023
Q2 | $134M | Sell |
5,018,765
-16,414
| -0.3% | -$439K | 0.02% | 471 |
|
|
2023
Q1 | $109M | Buy |
5,035,179
+1,355,137
| +37% | +$29.4M | 0.02% | 493 |
|
|
2022
Q4 | $87.7M | Buy |
3,680,042
+27,414
| +0.8% | +$653K | 0.01% | 519 |
|
|
2022
Q3 | $72M | Buy |
3,652,628
+1,414,774
| +63% | +$27.9M | 0.01% | 553 |
|
|
2022
Q2 | $43.6M | Sell |
2,237,854
-61,962
| -3% | -$1.21M | 0.01% | 919 |
|
|
2022
Q1 | $58.7M | Buy |
2,299,816
+1,244,045
| +118% | +$31.7M | 0.01% | 917 |
|
|
2021
Q4 | $26.6M | Buy |
1,055,771
+35,925
| +4% | +$904K | ﹤0.01% | 1209 |
|
|
2021
Q3 | $28.1M | Buy |
1,019,846
+1,001,922
| +5,590% | +$27.6M | ﹤0.01% | 1198 |
|
|
2021
Q2 | $569K | Buy |
17,924
+2,049
| +13% | +$65K | ﹤0.01% | 2325 |
|
|
2021
Q1 | $728K | Sell |
15,875
-76,945
| -83% | -$3.53M | ﹤0.01% | 2190 |
|
|
2020
Q4 | $3.68M | Buy |
+92,820
| New | +$3.68M | ﹤0.01% | 1485 |
|
|
2020
Q3 | – | Sell |
-133,371
| Closed | -$4.21M | – | 2613 |
|
|
2020
Q2 | $4.21M | Buy |
133,371
+37,939
| +40% | +$1.2M | ﹤0.01% | 1401 |
|
|
2020
Q1 | $2.09M | Buy |
+95,432
| New | +$2.09M | ﹤0.01% | 1488 |
|